Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS

[1]  K. Knights,et al.  Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance. , 2016, British journal of clinical pharmacology.

[2]  G. Asher,et al.  UGT concentrations in human rectal tissue after multidose, oral curcumin , 2016, Pharmacology research & perspectives.

[3]  T. Abe,et al.  Quantitative Targeted Absolute Proteomics for 28 Transporters in Brush-Border and Basolateral Membrane Fractions of Rat Kidney. , 2016, Journal of pharmaceutical sciences.

[4]  Yingying Guo,et al.  Ethnic Variability in the Expression of Hepatic Drug Transporters: Absolute Quantification by an Optimized Targeted Quantitative Proteomic Approach , 2015, Drug Metabolism and Disposition.

[5]  X. Chu,et al.  Interspecies Variability in Expression of Hepatobiliary Transporters across Human, Dog, Monkey, and Rat as Determined by Quantitative Proteomics , 2015, Drug Metabolism and Disposition.

[6]  R. Evers,et al.  Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex , 2014, Drug Metabolism and Disposition.

[7]  J. Manro,et al.  Utility of Oatp1a/1b-Knockout and OATP1B1/3-Humanized Mice in the Study of OATP-Mediated Pharmacokinetics and Tissue Distribution: Case Studies with Pravastatin, Atorvastatin, Simvastatin, and Carboxydichlorofluorescein , 2014, Drug Metabolism and Disposition.

[8]  Hendrik Neubert,et al.  Targeted Precise Quantification of 12 Human Recombinant Uridine-Diphosphate Glucuronosyl Transferase 1A and 2B Isoforms Using Nano-Ultra-High-Performance Liquid Chromatography/Tandem Mass Spectrometry with Selected Reaction Monitoring , 2013, Drug Metabolism and Disposition.

[9]  P. Borst,et al.  P-glycoprotein ABCB1: a major player in drug handling by mammals. , 2013, The Journal of clinical investigation.

[10]  Hendrik Neubert,et al.  Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. , 2013, Journal of proteome research.

[11]  X. Chu,et al.  Species differences in drug transporters and implications for translating preclinical findings to humans , 2013, Expert opinion on drug metabolism & toxicology.

[12]  K. Giacomini,et al.  Renal transporters in drug development. , 2013, Annual review of pharmacology and toxicology.

[13]  Tetsuya Terasaki,et al.  Simultaneous Absolute Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities , 2012, Drug Metabolism and Disposition.

[14]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[15]  Y. Lai,et al.  Absolute Difference of Hepatobiliary Transporter Multidrug Resistance-Associated Protein (MRP2/Mrp2) in Liver Tissues and Isolated Hepatocytes from Rat, Dog, Monkey, and Human , 2009, Drug Metabolism and Disposition.

[16]  Balázs Sarkadi,et al.  The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). , 2008, Drug discovery today.

[17]  E. van de Steeg,et al.  Species-Dependent Transport and Modulation Properties of Human and Mouse Multidrug Resistance Protein 2 (MRP2/Mrp2, ABCC2/Abcc2) , 2008, Drug Metabolism and Disposition.

[18]  Xingguo Cheng,et al.  Regulation of mRNA Expression of Xenobiotic Transporters by the Pregnane X Receptor in Mouse Liver, Kidney, and Intestine , 2006, Drug Metabolism and Disposition.

[19]  C. Klaassen,et al.  Tissue distribution and induction of the rat multidrug resistance-associated proteins 5 and 6. , 2006, Life sciences.

[20]  Thomas J. Raub,et al.  ALTERED HEPATOBILIARY DISPOSITION OF 5 (AND 6)-CARBOXY-2′,7′-DICHLOROFLUORESCEIN IN Abcg2 (Bcrp1) AND Abcc2 (Mrp2) KNOCKOUT MICE , 2006, Drug Metabolism and Disposition.

[21]  Yuan-qing Xia,et al.  SPECIES DIFFERENCES IN THE ELIMINATION OF A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONIST HIGHLIGHTED BY OXIDATIVE METABOLISM OF ITS ACYL GLUCURONIDE , 2005, Drug Metabolism and Disposition.

[22]  Curtis D. Klaassen,et al.  INDUCTION OF THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN FAMILY OF TRANSPORTERS BY CHEMICAL ACTIVATORS OF RECEPTOR-MEDIATED PATHWAYS IN MOUSE LIVER , 2005, Drug Metabolism and Disposition.

[23]  T. Horie,et al.  FUNCTIONAL ANALYSIS OF DOG MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2 (MRP2) IN COMPARISON WITH RAT MRP2 , 2005, Drug Metabolism and Disposition.

[24]  G. Kruh,et al.  The MRP family of drug efflux pumps , 2003, Oncogene.

[25]  J. Fenyk-Melody,et al.  Metabolism and disposition of gemfibrozil in Wistar and multidrug resistance-associated protein 2-deficient TR− rats , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[26]  C. Klaassen,et al.  The presence of xenobiotic transporters in rat placenta. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[27]  A. Schinkel,et al.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.

[28]  P. Jansen,et al.  The (patho)physiological functions of the MRP family. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[29]  R. Nation,et al.  Hepatic disposition of electrophilic acyl glucuronide conjugates. , 2000, Current drug metabolism.

[30]  Y. Sugiyama,et al.  Characterization of inducible nature of MRP3 in rat liver. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[31]  D. Keppler,et al.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. , 1999, Biochimica et biophysica acta.

[32]  Y. Sugiyama,et al.  Species differences in the transport activity for organic anions across the bile canalicular membrane. , 1999, The Journal of pharmacology and experimental therapeutics.

[33]  Y. Sugiyama,et al.  Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats. , 1998, Molecular pharmacology.

[34]  D. Keppler,et al.  cDNA Cloning of the Hepatocyte Canalicular Isoform of the Multidrug Resistance Protein, cMrp, Reveals a Novel Conjugate Export Pump Deficient in Hyperbilirubinemic Mutant Rats* , 1996, The Journal of Biological Chemistry.

[35]  A. V. van Herwaarden,et al.  The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. , 2006, Trends in pharmacological sciences.

[36]  B. Hirst,et al.  The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[37]  Y. Sugiyama,et al.  Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. , 1998, Annual review of pharmacology and toxicology.

[38]  R. Smith,et al.  The excretory function of bile : the elimination of drugs and toxic substances in bile , 1973 .